Waters[™]

Applikationsbericht

Quantification of 1,25-Dihydroxyvitamin D₂ and D₃ From Human Serum Using Immunopurification, ACQUITY UPLC, and Xevo TQ-S micro

Nikunj Tanna, Mark Wrona, Kelly Doering

Waters Corporation

Abstract

This application note demonstrates, a robust, selective, and sensitive analytical method for the quantification of 1,25 $(OH)_2$ Vitamin D₂ and D₃ from human serum was developed using the Waters ACQUITY UPLC System and Xevo TQ-S micro Mass Spectrometer. The Xevo TQ-S micro has the ideal combination of sensitivity, reproducibility, and versatility to provide an excellent option for all types of bioanalytical labs.

Benefits

- · Highly sensitive and robust method
- · Ability to detect 5 pg/mL using Waters ACQUITY UPLC and Xevo TQ-S micro systems
- $\cdot\,$ Accuracy and precision of <15% across the calibration range of 5–500 pg/mL

Introduction

Vitamin D is an important fat-soluble vitamin, which helps maintain bone health. Vitamin D exists in two primary forms: Vitamin D₃ (cholcalciferol) synthesized from 7-dehydrocholesterol when the skin is exposed to UV radiation from sunlight, and Vitamin D₂ (ergocalciferol) produced by plants and fungi through solar irradiation of ergosterol. Vitamin D is converted first to 25-hydroxyl (OH) Vitamin D by the liver via the CYP family of enzymes (Figure 1). 25 (OH) 25 (OH) Vitamin D is then hydroxylated into its biologically-active form: 1,25-dihydroxy (OH)₂ Vitamin D in the kidneys.




Figure 1. Process for conversion of 7-dehydrocholesterol to 1,25 (OH)₂ Vitamin D_{3} .²

This conversion is tightly controlled through a cascade pathway which involves calcium, phosphorous, parathyroid hormone, and Vitamin D receptors. Regulated by a feedback mechanism process, 1,25 (OH)₂ Vitamin D circulates in the pg/mL-level range in serum. Main application areas for the measurement of Vitamin D are in nutrition, pharmacokinetic studies, clinical studies, and quality control for foods and supplements.¹




Figure 2a. 1,25 di-hydroxy Vitamin D_2 . Figure 2b. 1,25 di-hydroxy Vitamin D_3 .

In recent years, LC-MS/MS assays – compared to immunoassays – have gained popularity as the method of choice for quantification of 1,25 (OH)₂ Vitamin D. LC-MS/MS assays provide orthogonal selectivity. The identity of every compound is based upon its retention time as well as its unique MRM transition. The addition of immunoaffinity using specific antibodies in sample cleanup adds an extra layer of selectivity to the assay.

LC-MS/MS is accepted by the FDA as the gold standard analytical technique for pharmacokinetic studies of small molecules. The FDA has set specific guidelines to be followed while developing and validating LC-MS/MS assays. These guidelines involve intra-day (within the same day) and inter-day (across multiple days) accuracy and precision studies, linearity, and reproducibility. The method presented here followed the Bioanalytical Method Validation guidelines set out by the FDA. Accuracy, precision, linear range, and reproducibility of the method was evaluated, and the method met the criteria detailed in the FDA guidelines.³

The data presented in this application note was generated using a Waters ACQUITY UPLC System and Xevo TQ-S micro Mass Spectrometer.

Experimental

Sample description

Commercially-available immunopurification kits were purchased from ALPCO Diagnostics and used to extract 1,25 (OH)₂ Vitamin D from 500 μ L of human serum. The eluate from the last step was evaporated to dryness. Samples were derivatized with PTAD (4-phenyl-1,2,4-triazoline-3,5-dione) using 100 μ L of 0.75 mg/mL PTAD in acetonitrile, which was added to each tube and allowed to incubate in the dark – at room temperature – for one hour. PTAD was then evaporated using a CryoVac system. The contents of the tubes were reconstituted using 50 μ L of 50:50 water-methanol mix. This solution was then transferred to LC MS/MS vials, and 20 μ L were injected into a column.

LC conditions

Instrument:	Waters ACQUITY UPLC
Column:	ACQUITY UPLC BEH C ₁₈ , 1.7 μm, 2.1 mm x 50 mm (P/N 1860002350)
Column temp.:	60 °C
Sample temp.:	4 °C
Injection volume:	20 µL
Flow rate:	0.500 mL
Mobile phase A:	100% water, 0.1% formic acid, 2 mM methylamine
Mobile phase B:	100% methanol, 0.1% formic acid, 2 mM methylamine
Gradient:	Start with 50% A and hold for two minutes. Change to 80% B between 2–4 minutes. Followed by one minute of flushing and one minute of equilibration.

MS conditions

Instrument:	Xevo TQ-S micro
Ionization mode:	ESI+
Transitions:	1,25 (OH) ₂ Vit D ₃ – 574.2>314.1
	1,25 (OH) ₂ Vit D ₂ – 635.3>314.1
	1,25 (OH) ₂ Vit D ₃ Int std – 580.3>314.1
	1,25 (OH) ₂ Vit D ₂ Int std – 641.3>314.1
Capillary voltage:	2.5 kV
Cone voltage:	25 V
Desolvation temp.:	500 °C
Desolvation gas:	1000 L/Hr
Cone gas:	25 L/Hr
Data management	

MassLynx 4.1

Results and Discussion

1,25 (OH)₂ Vitamin D is an important biomarker tested routinely in clinical and bioanalytical laboratories. The extremely low circulating levels of this molecule, coupled with lack of ionization in electrospray ionization mode, make this a challenging assay. The method described here combines affinity-based sample preparation combined with derivatization to increase ionization as an elegant solution for this analytically-difficult molecule.

Calibration curve and residual plots

Calibration curve from 5–500 pg/mL is linear and % bias across the range is <15% for both 1,25 (OH)₂ Vit D_2 and D_3 as shown in Figure 3a and 3b.




Figure 3a. Residual plot and calibration curve for 1,25 (OH)₂ Vit D_3 .




Figure 3b. Residual plot and calibration curve for 1,25 $(OH)_2$ Vit D_2 .

Inter-day accuracy and precision

Six replicates at low (30 pg/mL), mid (150 pg/mL), and high (300 pg/mL) QC levels were extracted and injected across three days. The intra-day and inter-day precision and accuracy were <15% at all levels as shown in Tables 1–4.

la			Mean	Std dev	% CV	% Bias	1b			Mean	Std dev	% CV	% Bias	lc			Mean	Std dev	% CV	% Bias
	30	25.8						150	160.7						300	270.4				
		31.4						150	138.9						300	280				
	30	26.4 28.5	29.18	2.89	9.91	-2.72		150	160.4	144.73	14.16	9.78	-3.51		300	260.6	273.82	9.95	3.63	-8.73
	30	28.5	29.10	2.09	9.91	-2.12		150	128.1	144.15	14.10	9.10	-3.31		300	268.6	213.02	9.95	3.03	-0.15
	30	33.3						150	131.5						300	289.4				
	30	29.7						150	148.8						300	273.9				
	30	34					8	150	145.3						300	295.7				
	30	26.9						150	159.5						300	333.1				
Intra-	30	32.3	32.83	4.77	14.51	9.44	Intra-		130.2	148.08	14.44	9.75	-1.28	Intra	-	296.6	303.38	17.24	5.68	1.13
day	30	29.3	52.05	4.11	14.51	3.44	day	150	135.1	140.00	14.44	5.15	-1.20	day	300	314.1	505.50	11.24	5.00	1.15
	30	40.8						150	168.4						300	295.2				
	30	33.7						150	150						300	285.6				
	30	25.6						150	156.4						300	269.5				
	30	32.1						150	134.2						300	329.1				
		30.5	28.75	3.27	11.37	-4.17	8	150	165.6	151.63	15.16	10.00	1.09		300	276.2	294.27	23.47	7.98	-1.91
	30	32.4	20.15	5.21	11.31			150	130.9	151.05	13.10	10.00	1.09		300	304.7	234.21	23.41	1.90	-1.91
	30	25.6						150	159.2						300	308.7				
	30	26.3						150	163.5						300	277.4				

Table 1a. Intra-day: 1,25 (OH)₂ D_2 – LQC (30 pg/mL). Table 1b. Intra-day: 1,25 (OH)₂ D_2 – MQC (150 pg/mL). Table 1c. Intra-day: 1,25 (OH)₂ D_2 – HQC (300 pg/mL).

		LQC	MQC	HQC
-	Mean	30.26	148.15	290.49
Intra-day	Std dev	3.98	14.01	20.99
	% CV	13.15	9.46	7.22
	% Bias	0.85	-1.23	-3.17

Table 2. Inter-day precision data: 1,25 (OH)₂ Vitamin D₂.

3a			Mean	Std dev	% CV	% Bias	Зb			Mean	Std dev	% CV	% Bias	3c			Mean	Std dev	% CV	% Bias
	30	32						150	168.4						300	334.3				
	30	27.2					_	150	170.8						300	336.3				
	30	27.7 34.2	31.47	3.21	10.20	4.89	_	150	167.8	166.90	3.48	2.09	-11.27		300	342.5	332.25	12.83	3.86	-10.75
	30	34.2	51.41	5.21	10.20	4.05	_	150	161.8	100.90	5.40	2.03	-11.21		300	332.2	332.23	12.05	5.00	-10.15
_	30	33.8					_	150	169.1						300	307.3				
	30	33.9					_	150	163.5						300	340.9				
		26.5						150	162.3						300	314.9				
	30	31.7						150	166.3						300	313.5				
Intra-	30	33.6	29.75	3.92	13.19	-0.83	Intra-	150	144.6	153.17	10.86	7.09	-2.11	Intra-		321.5	316.30	22.89	7.24	-5.43
day	30	34.4	23.13	J.JL	15.15	-0.05	day _	150	145.2	155.11	10.00	1.05	-2.11	day	300	274.9	510.50	22.05	1.24	-3.43
	30	25.8						150	140.8						300	341.6				
	30	26.5						150	159.8						300	331.4				
	30	26.5						150	157.4						300	260.1				
	30	25.8					1	150	154						300	316.8				
	30	29.5 29	28.72	2.62	9.13	-4.28		150	154.8	156.10	3.85	2.47	-4.07		300	307.5	293.32	27.33	9.32	2.23
	30	29	20.12	2.02	9.15	-4.20		150	151	150.10	5.05	2.41	-4.07		300	256.5	233.32	21.33	9.32	2.23
	30	28.3						150	157						300	309.1				
	30	33.2						150	162.4						300	309.9				

Table 3a. Intra-day: 1,25 (OH)₂ D₃ – LQC (30 pg/mL). Table 3b. Intra-day: 1,25 (OH)₂ D₃ – MQC (150 pg/mL). Table 3c. Intra-day: 1,25 (OH)₂ D₃ – HQC (300 pg/mL).

		LQC	MQC	HQC
Intra-day	Mean	29.98	158.72	313.96
	Std dev	3.31	8.92	26.32
	%CV	11.03	5.62	8.38
	% Bias	-0.07	-5.81	-4.65

Table 4. Inter-day precision data: 1,25 $(OH)_2$ Vitamin D_3 .

Injection reproducibility

The Waters ACQUITY UPLC and Xevo TQ-S micro displayed robust injection reproducibility as shown below. The % CV for the retention times was 0.32% (Figure 4a) and the % CV for analyte area counts was 5.21% (Figure 4b) – both of which are well within the acceptable criteria.




Figure 4a. % CV for retention time over 100 injections. Figure 4b. % CV for analyte area counts over 100 injections.

Instrument dynamic range

The analytical range for this method is from 5–500 pg/mL and covers the relevant concentrations typically found in serum. 1,25 (OH)₂ Vitamin D showed linearity from 50 pg/mL–1 μ g/mL using the ACQUITY UPLC and TQ-S micro for the method described here.




Figure 5. Linear dynamic range >4x.

Conclusion

A robust, selective, and sensitive analytical method for the quantification of 1,25 (OH)₂ Vitamin D₂ and D₃ from human serum was developed using the Waters ACQUITY UPLC System and Xevo TQ-S micro Mass Spectrometer. A limit of quantification of 5 pg/mL was readily achieved while maintaining excellent linearity. Calibration curves for both 1,25 (OH)₂ D₂ and D₃ were linear over the range of 5–500 pg/mL with r²>0.99. Across three days, the intra- and inter-day CV as well as the % bias were <15% for both 1,25 (OH)₂ Vitamin D ₂ and D₃. Injection reproducibility was excellent with % CV <0.32% for retention time and <5.5% for area counts.

Today's analytical laboratories are becoming more diverse and multi-functional. Lab managers are expected to diversify their analytical platforms within limited lab spaces. The Xevo TQ-S micro has the ideal combination of sensitivity, reproducibility, and versatility to provide an excellent option for all types of bioanalytical labs.

References

- van den Ouweland, M. W. J.; Vogeser, M.; Bächer, S. Vitamin D and metabolites measurement by tandem mass spectrometry. *Rev Endocr Metab Disord*. (2013): 159–184.
- 2. Jensen, M. J. Vitamin D and male reproduction. Nature Reviews Endocrinology. (2014): 175–186.
- 3. Guidance for Industry, Bioanalytical Method Validation. Food and Drug Administration (2001).

Featured Products

ACQUITY UPLC System <https://www.waters.com/514207>

Xevo TQ-S micro Triple Quadrupole Mass Spectrometry https://www.waters.com/134798856>

MassLynx Mass Spectrometry Software https://www.waters.com/513164>

720005679, April 2016

©2019 Waters Corporation. All Rights Reserved.